@zroger73@SawyerMerritt That’s been our experience too. We had several generations of Civics, Accords and Odessys. Honda used to make very dependable if not flashy vehicles. They seem to have lost their way 10-15 years ago.
@JEBistline The trends for AI data centers will follow these curves. Energy generation is the bottleneck and Texas seems to be leading the way to remove this bottleneck. Such data centers will be a boon to local economies if they can be powered without overly straining the grid.
@Nature@RySciComms Another example of the impact of Cell Therapy. This patient’s entire life has been changed by a single dose. She went from daily blood transfusions to having her life back. That’s ideally how medicines should work.
@mukundiyngr I believe the improvement in melanoma is just as significant where immunotherapies have been transformation for a formerly difficult to treat solid tumor.
@PeterDiamandis The concept of designing your business for an age of abundance caught my attention. When we reach such abundance (by 2030?!) I can’t help but believe that demand will explode for next generation, single-dose, curative cell and gene therapies that may be cost prohibitive today…
@US_FDA So glad to see new focus on Biosimilar regulatory red tape. There is no doubt that needless regulatory hurdles hamstrung biosimilars in the US. A vibrant biosimilar ecosystem will lower healthcare costs and stimulate innovation.
@BenjaminBadejo Whether by an intentional strategy or luck, Apple is now positioned so well to play in the AI race with local models running on Mac minis and Studios. The next version of the Studio with M5 together with the new mini open source models will be a game changer.
@OwenGregorian I for one am exciting to see a government agency embracing a forward-looking perspective. Yes you will need proper oversight especially in the beginning. This is how we advance. Taking 12 months for humans to review 10s of 1000s of pages of data seems archaic and slow.
@BiotechTVHQ@LegendBiotech What amazing results! I especially appreciated the health economics segment. 25 months after carvyti vs standard of care the costs were $0.7M vs $1.6. Plus carvyti is of course one and done, while the SoC has frequent treatments. Cell therapy is revolutionary.